Avidity Biosciences Inc
NASDAQ:RNA

Watchlist Manager
Avidity Biosciences Inc Logo
Avidity Biosciences Inc
NASDAQ:RNA
Watchlist
Price: 71.35 USD 0.07% Market Closed
Market Cap: 10.8B USD

Wall Street
Price Targets

RNA Price Targets Summary
Avidity Biosciences Inc

Wall Street analysts forecast RNA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RNA is 74.07 USD with a low forecast of 65.65 USD and a high forecast of 100.8 USD.

Lowest
Price Target
65.65 USD
8% Downside
Average
Price Target
74.07 USD
4% Upside
Highest
Price Target
100.8 USD
41% Upside
Avidity Biosciences Inc Competitors:
Price Targets
PHM
Pharma Mar SA
34% Upside
VITR
Vitrolife AB
38% Upside
IVA
Inventiva SA
220% Upside
IMDX
Insight Molecular Diagnostics Inc
40% Upside
PBYI
Puma Biotechnology Inc
15% Downside
CPRX
Catalyst Pharmaceuticals Inc
54% Upside
IMNM
Immunome Inc
29% Upside
2126
JW (Cayman) Therapeutics Co Ltd
101% Upside

Revenue
Forecast

Revenue Estimate
Avidity Biosciences Inc

For the last 5 years the compound annual growth rate for Avidity Biosciences Inc's revenue is 36%. The projected CAGR for the next 3 years is 227%.

36%
Past Growth
227%
Estimated Growth
Estimates Accuracy
5%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Avidity Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat

Net Income
Forecast

Net Income Estimate
Avidity Biosciences Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-66%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RNA's stock price target?
Price Target
74.07 USD

According to Wall Street analysts, the average 1-year price target for RNA is 74.07 USD with a low forecast of 65.65 USD and a high forecast of 100.8 USD.

What is Avidity Biosciences Inc's Revenue forecast?
Projected CAGR
227%

For the last 5 years the compound annual growth rate for Avidity Biosciences Inc's revenue is 36%. The projected CAGR for the next 3 years is 227%.

Back to Top